KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Operating Leases: 2019-2025

Historic Operating Leases for Arbutus Biopharma (ABUS) over the last 7 years, with Sep 2025 value amounting to $391,000.

  • Arbutus Biopharma's Operating Leases fell 60.02% to $391,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $391,000, marking a year-over-year decrease of 60.02%. This contributed to the annual value of $806,000 for FY2024, which is 39.99% down from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's Operating Leases is $391,000, which was down 32.00% from $575,000 recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Operating Leases peaked at $2.5 million during Q1 2021, and registered a low of $391,000 during Q3 2025.
  • Moreover, its 3-year median value for Operating Leases was $1.1 million (2024), whereas its average is $1.1 million.
  • Data for Arbutus Biopharma's Operating Leases shows a maximum YoY tumbled of 60.02% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Operating Leases stood at $2.2 million in 2021, then decreased by 18.65% to $1.8 million in 2022, then fell by 26.01% to $1.3 million in 2023, then crashed by 39.99% to $806,000 in 2024, then slumped by 60.02% to $391,000 in 2025.
  • Its last three reported values are $391,000 in Q3 2025, $575,000 for Q2 2025, and $626,000 during Q1 2025.